Andina III and EMMAC Life Sciences Limited said today they have mutually terminated negotiations regarding a proposed business combination. The parties signed a non-binding letter of intent on July 22, in which EMMAC was expected to trade on the NASDAQ. Both sides cited “challenging global economic conditions” among the reasons for terminating the deal. EMMAC bills itself as Europe’s largest independent cannabis company. Andina shareholders last week approved an extension of the SPAC’s deadline to close a deal. Andina was initially capitalized with a $100M IPO. Read more.
Related Posts
OTR Units Begin Separate Trading
The SPAC intends to acquire a business with an enterprise value of approximately $500 million to $2.5 billion.
Pegasus Digital Mobility Earmarks 2.8M+ Class B Shares for Investor Incentives
The SPAC has a business combination agreement with Gebr. Schmid Group and an April 30 deadline to close. The target is a global solutions provider for the high-tech electronic, photovoltaics, glass, and energy systems industries.
Concord Acquisition III Expects to Sign NRA Covering 8.6M Shares Ahead of Extension Vote
Concord last week said it entered into a non-binding letter of intent for a business combination “with a well-established semiconductor supplier” and that the target has received non-binding letters of intent from investors to provide financing in an amount sufficient to support the closing of the proposed merger.
Maquia Capital Adds $13M to its Coffers with Over-Allotment Closing
Maquia is targeting technology-focused middle market and emerging growth companies in North America. The SPAC raised $160 million in an IPO earlier this month.